Health and Healthcare
Auxilium Scores on Pfizer Pact (AUXL, PFE)
Published:
Last Updated:
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) is responding well in pre-market trading after the company signed an overseas commercialization agreement with Pfizer, Inc. (NYSE: PFE). The pact covers Auxilium’s Xiaflex, a treatment for hand and urological disorders related to hardening collagen.
The terms of the deal appear to call for an upfront payment of $75million. The company is also eligible to receive milestone payments ofup to $410 million depending upon goals and targets reached.
Auxilium is set to receive increasing tiered royalty payments onPfizer’s Xiaflex sales. This could reach up to 25% since Auxilium willmake the drug. Pfizer also expects to file for approval in the U.S.in 2009 and to file for approval in the E.U. in 2010.
As of yesterday’s close, Auxilium’s market cap was $967 million basedupon a closing bell price of $22.89. Its 52-week trading range is$15.44 to $42.75, and shares are trading up 15% at $26.50 in pre-markettrading.
Jon C. Ogg
December 18, 2008
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
